CFRX

ContraFect Corporation [CFRX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CFRX Stock Summary

Top 10 Correlated ETFs

CFRX


Top 10 Correlated Stocks

CFRX


In the News

06:00 26 Mar 2023 CFRX

Penny Stock Investing for Passive Income: Opportunities and Risks

Use these tips for making passive income with penny stocks The post Penny Stock Investing for Passive Income: Opportunities and Risks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

08:27 26 Mar 2023 CFRX

Why Is ContraFect (CFRX) Stock Up 20% Today?

ContraFect (NASDAQ: CFRX ) stock is rising higher on Tuesday as investors await news about its potential delisting from the Nasdaq Capital Market. ContraFect last updated investors on Friday about its delisting situation.

08:38 26 Mar 2023 CFRX

Why Is ContraFect (CFRX) Stock Down 23% Today?

ContraFect (NASDAQ: CFRX ) stock is falling on Friday after the company provided an update on its potential delisting from the Nasdaq Capital Market. ContraFect notes in a filing with the SEC that the Nasdaq staff has rejected its request for continued listing on the exchange.

09:21 26 Mar 2023 CFRX

These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022

The healthcare industry is now starting to shift its focus away from the coronavirus pandemic to work on its core activities.

11:10 26 Mar 2023 CFRX

Why Is ContraFect (CFRX) Stock Down 80% Today?

A Phase 3 trial of ContraFect's treatment for antibiotic-resistant infections has been stopped, and CFRX stock is plunging. The post Why Is ContraFect (CFRX) Stock Down 80% Today?

10:18 26 Mar 2023 CFRX

Penny Stocks To Buy Today? 3 To Watch With Analyst Targets Up To 675%

Penny stocks to buy according to analysts. The post Penny Stocks To Buy Today?

02:30 26 Mar 2023 CFRX

Biopharmaceutical Stocks: The Bottoming Process Is Playing Out

Three weeks ago, I suggested that the severe correction in biopharmaceutical stocks had ended. I expect the bottoming process to be choppy with a bias to the upside. The antecedent cause of the decline was the "Class of 2021 IPOs", which featured many companies with preclinical compounds, yet valuations exceeded $1 billion.

07:30 26 Mar 2023 CFRX

ContraFect to Present Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Combat MRSA at ASM Microbe 2022

YONKERS, N.Y., June 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that the Company has been selected to present two posters at the ASM Microbe Conference to be held in Washington, D.C. from June 9-13, 2022. The data being presented features the Company's Breakthrough Therapy designated product candidate, exebacase, currently being studied in a pivotal Phase 3 superiority design trial.

08:30 26 Mar 2023 CFRX

ContraFect to Present at the Maxim Group 2022 Virtual Growth Conference

YONKERS, N.Y., March 21, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that Roger Pomerantz, M.D., President, Chief Executive Officer and Chairman of ContraFect, will participate in a fireside chat at the Maxim Group 2022 Virtual Growth Conference, which is being held virtually from March 28–30, 2022. The live fireside chat will be with Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at Maxim Group on Monday, March 28, 2022 at 2:00pm ET.

07:30 26 Mar 2023 CFRX

ContraFect to Present at the SVB Leerink 11th Annual Global Healthcare Conference

YONKERS, N.Y., Feb. 10, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that Roger Pomerantz, M.D., President, Chief Executive Officer and Chairman of ContraFect, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference, which is being held virtually from February 14–18, 2022. The fireside chat will be held on Thursday, February 17, 2022 at 10:00 AM ET.

CFRX Financial details

Company Rating
Neutral
Market Cap
2.7M
Income
-75.6M
Revenue
0
Book val./share
-6.31
Cash/share
35.89
Dividend
-
Dividend %
-
Employees
38
Optionable
No
Shortable
Yes
Earnings
22 Mar 2023
P/E
-0.01
Forward P/E
-
PEG
-0
P/S
-
P/B
-0.33
P/C
0.06
P/FCF
-0.12
Quick Ratio
0.74
Current Ratio
0.84
Debt / Equity
-8.42
LT Debt / Equity
-0.75
-
-
EPS (TTM)
-153.75
EPS next Y
-
EPS next Q
-
EPS this Y
-27.96%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-5.65%
-
-
-
-
SMA20
-47.78%
SMA50
-75.46%
SMA100
-85.14%
Inst Own
28.74%
Inst Trans
6.19%
ROA
-328%
ROE
-339%
ROC
96.11%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
1.3M
Shs Float
479.06K
-
-
-
-
Target Price
-
52W Range
1.75-363.2
52W High
-99.43%
52W Low
+108%
RSI
35.06
Rel Volume
0.18
Avg Volume
667.57K
Volume
121.61K
Perf Week
-0.48%
Perf Month
-58.4%
Perf Quarter
-84.52%
Perf Half Y
-87.23%
-
-
-
-
Beta
0.492458
-
-
Volatility
0.09%, 1.02%
Prev Close
8.33%
Price
2.08
Change
6.95%

CFRX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
00000
Net income per share
-223.29-396.35-123.57-98.95-71.28
Operating cash flow per share
-352.96-276.18-264.89-116.63-144.53
Free cash flow per share
-352.96-277.59-265.08-116.63-144.53
Cash per share
674.21320.29233.56149.33190.78
Book value per share
448.8658.29150.1344.35173.53
Tangible book value per share
448.8658.29150.1344.35173.53
Share holders equity per share
448.8658.29150.1344.35173.53
Interest debt per share
006.12.2711.48
Market cap
56.15M116.38M51.42M114.96M59.87M
Enterprise value
49.16M108.06M31.13M100.12M46.48M
P/E ratio
-3.62-3.09-4.02-4.08-2.95
Price to sales ratio
00000
POCF ratio
-2.29-4.43-1.87-3.46-1.46
PFCF ratio
-2.29-4.41-1.87-3.46-1.46
P/B Ratio
1.8213.319.111.21
PTB ratio
1.8213.319.111.21
EV to sales
00000
Enterprise value over EBITDA
-3.21-2.88-2.47-3.58-2.31
EV to operating cash flow
-2-4.12-1.13-3.02-1.13
EV to free cash flow
-2-4.09-1.13-3.02-1.13
Earnings yield
-0.28-0.32-0.25-0.24-0.34
Free cash flow yield
-0.44-0.23-0.53-0.29-0.69
Debt to equity
0.614.931.253.050.35
Debt to assets
0.380.830.560.750.26
Net debt to EBITDA
0.460.221.610.530.66
Current ratio
11.025.423.067.85.16
Interest coverage
00000
Income quality
1.580.72.141.182.03
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00.01000
Capex to revenue
00000
Capex to depreciation
0-0.88-0.1200
Stock based compensation to revenue
00000
Graham number
1.5K720.98646.06314.23527.54
ROIC
-0.76-2.11.74-1.87-1.52
Return on tangible assets
-0.31-1.15-0.37-0.55-0.3
Graham Net
400.8632.8345.5914.04129.68
Working capital
44.28M25.64M20.7M41.23M50.69M
Tangible asset value
31.19M5.54M15.54M12.62M49.38M
Net current asset value
29.71M4.11M11.3M8.79M45.48M
Invested capital
000.040.050.07
Average receivables
00000
Average payables
1.43M1.36M2.02M2.21M2.1M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.5-6.8-0.82-2.23-0.41
Capex per share
0-1.4-0.1900

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-09-302021-12-312022-03-312022-06-30 2022-09-30
Revenue per share
00000
Net income per share
0-41.25-41-36.79-34.71
Operating cash flow per share
-66.2226.31-23.93-29.66-19.64
Free cash flow per share
-66.2226.31-23.93-29.66-19.67
Cash per share
0110.418655.5335.89
Book value per share
107.81100.4361.0126.21-6.31
Tangible book value per share
107.81100.4361.0126.21-6.31
Share holders equity per share
107.81100.4361.0126.21-6.31
Interest debt per share
8.156.646.466.266.08
Market cap
159.3M103.45M143.56M120.75M6.61M
Enterprise value
163.31M90.06M137.1M114.28M4.92M
P/E ratio
0-1.28-1.78-1.67-0.1
Price to sales ratio
00000
POCF ratio
-4.898-12.2-8.28-0.68
PFCF ratio
-4.898-12.2-8.28-0.68
P/B Ratio
3.012.14.799.37-2.13
PTB ratio
3.012.14.799.37-2.13
EV to sales
00000
Enterprise value over EBITDA
-14.11-4.43-6.81-6.51-0.29
EV to operating cash flow
-5.026.96-11.65-7.84-0.51
EV to free cash flow
-5.026.96-11.65-7.84-0.51
Earnings yield
0-0.2-0.14-0.15-2.58
Free cash flow yield
-0.20.13-0.08-0.12-1.46
Debt to equity
0.470.350.872.17-8.42
Debt to assets
0.320.260.460.681.13
Net debt to EBITDA
-0.350.660.320.370.1
Current ratio
7.485.163.161.830.84
Interest coverage
0000-2.43K
Income quality
0-0.640.580.810.57
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00000
Graham number
0305.31237.24147.2970.21
ROIC
0-0.45-0.56-1.9213.34
Return on tangible assets
0-0.3-0.36-0.44-0.74
Graham Net
-50.5275.0533.03-1.24-17.27
Working capital
64M50.69M35.71M17.11M-3.73M
Tangible asset value
53.01M49.38M30M12.89M-3.1M
Net current asset value
49.04M45.48M26.23M9.8M-6.09M
Invested capital
0.080.070.110.24-0.96
Average receivables
00000
Average payables
3.01M2.68M5.33M9.77M13.31M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
0-0.41-0.67-1.45.5
Capex per share
00000

CFRX Frequently Asked Questions

What is ContraFect Corporation stock symbol ?

ContraFect Corporation is a US stock , located in Yonkers of Ny and trading under the symbol CFRX

What is ContraFect Corporation stock quote today ?

ContraFect Corporation stock price is $2.08 today.

Is ContraFect Corporation stock public?

Yes, ContraFect Corporation is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap